Drugs@FDA: FDA-Approved Drugs
New Drug Application (NDA): 213004
Company: REDHILL
Company: REDHILL
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
---|---|---|---|---|---|---|---|
TALICIA | AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN | 250MG;EQ 10MG BASE;12.5MG | CAPSULE, DELAYED RELEASE;ORAL | Prescription | None | Yes | Yes |
Original Approvals or Tentative Approvals
Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
---|---|---|---|---|---|---|---|
11/01/2019 | ORIG-1 | Approval | Type 4 - New Combination | PRIORITY |
Label (PDF)
Letter (PDF) Review |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213004lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/213004Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/213004Orig1s000TOC.cfm |
Supplements
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert | Note | Url |
---|---|---|---|---|---|
05/01/2024 | SUPPL-14 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213004s014lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/213004Orig1s014ltr.pdf | |
07/18/2023 | SUPPL-12 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213004s012lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/213004Orig1s012ltr.pdf | |
09/08/2023 | SUPPL-10 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213004s010lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/213004Orig1s010ltr.pdf | |
03/04/2022 | SUPPL-7 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213004s007lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/213004Orig1s007ltr.pdf | |
10/01/2021 | SUPPL-4 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213004s004lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/213004Orig1s004ltr.pdf | |
11/27/2020 | SUPPL-2 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213004s002lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/213004Orig1s002ltr.pdf |
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert |
Note | Url |
---|---|---|---|---|---|
05/01/2024 | SUPPL-14 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213004s014lbl.pdf | |
09/08/2023 | SUPPL-10 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213004s010lbl.pdf | |
07/18/2023 | SUPPL-12 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213004s012lbl.pdf | |
03/04/2022 | SUPPL-7 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213004s007lbl.pdf | |
10/01/2021 | SUPPL-4 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213004s004lbl.pdf | |
11/27/2020 | SUPPL-2 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213004s002lbl.pdf | |
11/01/2019 | ORIG-1 | Approval | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213004lbl.pdf |